When transplants are performed, patients have to take drugs to suppress the immune system, keeping it from rejecting the new cells it sees as foreign. Unfortunately, the suppression can also leave patients vulnerable to attacks from routine viruses (such as cytomegalovirus) that the immune system usually handles easily.
To control the cytomegalovirus, Vical
Total payments of $130 million aren't really all that much for a phase-3-ready compound; consider that Micromet's
While the vaccine will have a much smaller market than vaccines like Pfizer's
Of course, talk of sales and royalties is a little premature at this point. TransVax needs to prove successful in its yet-to-be-started phase 3 trial before we can transplant those milestone and royalty payments to the revenue line.
Looking for the Vical of the new technology revolution? Grab this free report and find out which company Fool analysts think will win.
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Click here to see his holdings and a short bio. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool's disclosure policy is an organ donor and thinks you should be, too.